5Y Capital

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

VisionNav Robotics Limited designs, develops, and manufactures industrial vehicle vision driverless navigation equipment for indoor and outdoor scenes. Its products include vision navigation tray unmanned forklift, visual navigation balance heavy unmanned forklift, vision navigation forward-moving unmanned forklift, visual navigation unmanned tractor, and industrial vehicle driverless system solution. The company serves to e-commerce logistics, aviation logistics, third party logistics, retail fast moving goods, and home appliance sectors. The company was founded in 2015 and is based in Shenzhen, China.

Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.

Regenerative Bio is a pioneering biotechnology company focused on anti-aging solutions through the integration of artificial intelligence and advanced computing technologies. The company is dedicated to researching and developing ingredients, formulations, and therapies aimed at mitigating the effects of aging and enhancing overall health. By leveraging AI, quantum physics, and high-throughput preparation methods, Regenerative Bio seeks to improve cellular health and energy metabolism, ultimately promoting longer, healthier lives. Their innovative approach combines pharmaceutical technology with biological research, addressing age-related health issues and contributing to the field of longevity science.

ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.

Developer of an artificial intelligence platform designed to optimize pharmaceutical formulation processes. The company's software helps pharmaceutical companies accelerate the movement of new drugs in the pipeline through optimizing pre-clinical trial operations, enabling users to efficiently conduct research and design.

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based (RNA and DNA) therapeutics for treatment of cancer and infectious diseases.

Zhongke Guosheng is a bio-based materials R&D firm that designs and develops furan-based bio-based materials.

Developer of biocomputing technology. The company develops synthetic biology platform to improve the efficiency of biotech R&D, making biological product development as simple and efficient as software development.

Signet Therapeutics is a biopharmaceutical startup focusing on developing innovative targeted cancer drugs using novel disease models.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

Etern is developing small molecule innovative drugs for oncology therapies.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

ONES.AI is a technology company specializing in enterprise-level research and development management solutions. Founded in 2015, the company offers a suite of tools designed to enhance project and program management. Its offerings include ONES Project for overseeing project progress, ONES Plan for managing programs, ONES Wiki for repository management, ONES TestCase for managing test cases and plans, and ONES Pipeline for continuous integration and delivery management. ONES.AI has served over 20,000 enterprises and organizations across various sectors, including new retail, gaming, live broadcasting, fintech, and artificial intelligence. The company's platform aims to improve management effectiveness and operational efficiency for its clients.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

X-EPI is a Nanjing city-based startup aimed at building up China’s own EDA (Electronic Design Automation) industrial software technology.

Beijing Naxions Technology Co., Ltd. is a healthcare-focused company that specializes in providing digital marketing services tailored for the pharmaceutical industry. Founded in 2014 and headquartered in Chaoyang District, China, with additional offices in Shanghai, Naxions has developed a software-as-a-service (SaaS) platform designed to enhance pharmaceutical sales management. The platform offers a range of services, including data capture, cleaning, and analysis, alongside features for content sharing and project management. By leveraging internet technology, Naxions aims to support pharmaceutical enterprises in developing their brand image and increasing market awareness through real-time data analysis and visualization.

neoX BIOTECH is a biotechnology company that develops antigen-based cancer vaccine through a deep understanding of biophysics and the use of artificial intelligence. It develops a neoantigen prediction and TCR screening platform. The company was founded in 2018 and is based in Beijing, China.

Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.

Evonetix Ltd is a biotechnology company based in Little Chesterford, United Kingdom, established in 2015. The company focuses on developing innovative technology for the parallel synthesis of DNA on silicon arrays, thereby advancing the field of synthetic biology. By employing novel techniques, Evonetix aims to synthesize DNA with higher accuracy and scale, which enhances accessibility for researchers. This platform enables scientists to utilize synthetic biology on a previously unattainable scale, fundamentally changing how DNA is accessed, produced, and utilized for gene synthesis. The engineering team at Evonetix boasts extensive experience in creating high-integrity automated systems, bringing together a diverse range of expertise from various scientific and engineering disciplines to support its mission.

Adjuvance Technologies, Inc. is a biopharmaceutical company based in Lincoln, Nebraska, founded in 2009. The company specializes in the design and manufacture of adjuvant molecule vaccines, which enhance the immune response in vaccination. Its product offerings include Saponex, a synthetic version of the naturally occurring adjuvant QS-21; TQL1055, a synthesized novel analogue; and Triterpene Saponin Synthesis Technology (TriSST), which focuses on the synthesis of novel compositions. Additionally, Adjuvance provides TiterQuil, a collection of unique molecules that do not occur in nature. Through its innovative approach, Adjuvance Technologies aims to advance vaccine efficacy and contribute to public health.

Xinjunte has focused on the research and development of intelligent medical devices for bone surgery, and is committed to providing more efficient and safe medical devices.

ONES.AI is a technology company specializing in enterprise-level research and development management solutions. Founded in 2015, the company offers a suite of tools designed to enhance project and program management. Its offerings include ONES Project for overseeing project progress, ONES Plan for managing programs, ONES Wiki for repository management, ONES TestCase for managing test cases and plans, and ONES Pipeline for continuous integration and delivery management. ONES.AI has served over 20,000 enterprises and organizations across various sectors, including new retail, gaming, live broadcasting, fintech, and artificial intelligence. The company's platform aims to improve management effectiveness and operational efficiency for its clients.

Redesign Science Inc is a biotechnology company based in New York, established in 2017, that specializes in small molecule drug discovery. The company employs advanced techniques, including first-principles physics and artificial intelligence, to simulate protein targets at the atomic level. This approach allows Redesign Science to identify subtle drug opportunities that conventional computational models may overlook. By focusing on the development of first-in-class small molecules, the company aims to address emerging and challenging targets associated with significant unmet medical needs. Their innovative methodologies not only enhance the understanding of biological pathways and disease mechanisms but also drive the commercialization of new therapeutic solutions.

Inotrem S.A. is a biotechnology company based in Paris, France, specializing in the discovery and development of innovative treatments for inflammatory pathologies, particularly in critical care settings. Founded in 2013, the company focuses on immunotherapy and has created a novel immunomodulation approach targeting the TREM-1 pathway to manage excessive inflammation. Its lead product, nangibotide (also known as LR12), is a first-in-class TREM-1 inhibitor designed to address severe conditions such as septic shock and myocardial infarction. Inotrem is also advancing a program aimed at treating chronic inflammatory diseases, leveraging its proprietary technology platform to develop new therapeutic modalities.

Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.

ONES.AI is a technology company specializing in enterprise-level research and development management solutions. Founded in 2015, the company offers a suite of tools designed to enhance project and program management. Its offerings include ONES Project for overseeing project progress, ONES Plan for managing programs, ONES Wiki for repository management, ONES TestCase for managing test cases and plans, and ONES Pipeline for continuous integration and delivery management. ONES.AI has served over 20,000 enterprises and organizations across various sectors, including new retail, gaming, live broadcasting, fintech, and artificial intelligence. The company's platform aims to improve management effectiveness and operational efficiency for its clients.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.

Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.

InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductor, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.

DNAtrix, Inc. is a clinical stage biotechnology company based in Houston, Texas, specializing in virus-driven immunotherapies for cancer treatment. The company develops modified viruses designed to selectively target and kill cancer cells, with its lead product, DNX-2401, focused on glioblastoma, an aggressive and currently incurable brain tumor. This oncolytic immunotherapy has shown promising early results, having been administered to over 35 patients. In addition to DNX-2401, DNAtrix is advancing other therapies, including DNX-2440 and DNX-2450 for solid tumors, and MYX-135 for hematological malignancies. The company aims to expand its platform technology to address a broader range of cancers, including brain metastases, ovarian, and pancreatic cancer. DNAtrix has formed a strategic partnership with Valo Therapeutics to enhance its research and development efforts.

Senhwa Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2012 and headquartered in New Taipei City, Taiwan, the company is advancing several drug candidates through clinical trials. Notably, CX-4945 is undergoing phase I/II trials for cholangiocarcinoma in combination with gemcitabine and cisplatin, while CX-5461 is being tested in phase I studies for advanced hematologic malignancies and solid tumors, including breast cancer. Additionally, CX-4945 is involved in trials for advanced basal cell carcinoma and recurrent SHH medulloblastoma through pediatric brain tumor consortium studies. Senhwa Biosciences aims to identify and develop therapies that have the potential to significantly enhance treatment outcomes for patients, focusing on underexploited targets that could improve the standard of care.

Envisia Therapeutics Inc. is a biotechnology company dedicated to discovering and developing innovative therapies for ocular conditions. Founded in 2013 and based in Durham, North Carolina, the company addresses significant unmet medical needs in ophthalmology, particularly for conditions like glaucoma. Envisia's lead product, ENV515, is a prostaglandin analogue formulated with a biodegradable PRINT particle technology, designed to provide sustained intraocular pressure reduction over several months. The company's research and development efforts focus on overcoming barriers associated with traditional ocular therapies, such as poor drug uptake and systemic side effects, by utilizing biocompatible polymers and extended-release delivery systems. With an increasing demand for effective ocular therapeutics due to a rapidly aging population, Envisia aims to significantly improve patient outcomes and adherence to treatment protocols in the field of eye care.

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.

NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

Clean Membranes, Inc. produces anti-fouling membranes for various water treatment applications. It offers products for the desalination of seawater and brackish water; purification of surface and well water; municipal and industrial wastewater treatment; pharmaceutical and food industry; oil and gas extraction; industrial and pharmaceutical market; seawater desalination; and producing potable water from brackish water applications. The company was incorporated in 2008 and is based in Lexington, Massachusetts.

Procarta Biosystems Ltd, founded in 2007 and based in Norwich, United Kingdom, develops innovative antibacterial therapies using a DNA-based platform. The company focuses on addressing the growing challenge of drug-resistant bacterial strains by offering a range of proprietary nanoparticles, collectively referred to as "snare." These nanoparticles facilitate the delivery of oligonucleotides targeting various bacterial pathogens, including MRSA, through both topical and intravenous solutions. Additionally, Procarta's therapies include a broad-spectrum treatment for Gram-negative infections, particularly those acquired in hospital settings, and a specific solution aimed at preventing the recurrence of Clostridium difficile infections. Originating as a spin-out from the John Innes Centre, Procarta has garnered early-stage investment and operates within the Norwich Research Park, contributing to advancements in antibiotic development for challenging infections.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in Morrisville, North Carolina, that specializes in the development and commercialization of human therapeutics. The company utilizes its proprietary PRINT technology, a particle engineering platform that allows for the precise production of uniform drug particles, aimed at improving the safety, efficacy, and performance of various therapies. Liquidia is currently advancing two key product candidates: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for addressing local post-operative pain. In addition to its internal pipeline, Liquidia collaborates with leading pharmaceutical companies to leverage its PRINT technology across multiple therapeutic areas and drug types. The company also offers strategy and commercialization services for rare disease pharmaceutical products, including a generic formulation of treprostinil for pulmonary arterial hypertension. Founded in 2004, Liquidia Technologies continues to focus on transforming patient care through innovative therapeutic solutions.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.

360Guanxi (formerly eChinaChem) is an integrated media company for the Chinese chemical, pharmaceutical and life science industries.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.

The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...

MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.